<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538484</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS# 15-2100</org_study_id>
    <secondary_id>HSC20150602H</secondary_id>
    <nct_id>NCT02538484</nct_id>
  </id_info>
  <brief_title>Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects</brief_title>
  <official_title>A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women With Estrogen Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese,
      postmenopausal breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, comparative, three arm, short term, non-interventional study with correlative
      biomarker endpoints. Sixty (60) obese (â‰¥ 30 BMI) newly diagnosed ER+ postmenopausal breast
      cancer patients will be recruited to participate in a short term (30 day) Phase 0 biomarker
      evaluation study prior to surgical resection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in levels of aromatase target gene.</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum levels of PGE2 (prostaglandin E2).</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg by mouth daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fish oil 2700 mg by mouth daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole and Fish Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Aromatase inhibitor</description>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_label>Letrozole and Fish Oil</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Omega-3 free fatty acid</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_label>Letrozole and Fish Oil</arm_group_label>
    <other_name>Omega-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Postmenopausal as confirmed in medical history

          -  Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's IRB (Institutional Review
             Board)/Ethics Committee.

          -  Estrogen receptor positive breast cancer. Body mass index of 30 or greater.

          -  Consented for tissue collection on CTRC (Cancer Therapy and Research Center)
             repository 07-32

        Exclusion Criteria:

          -  Cachexia

          -  Active systemic illness (infection including viral illnesses such as Hepatitis and
             HIV)

          -  Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free
             fatty acid supplementation within the last 60 days (defined as greater than or equal
             to 7 consecutive days)

          -  Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days

          -  History of medical noncompliance

          -  Scheduled date of surgical resection that would limit the amount of time taking the
             intervention to less than 21 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Brenner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>ctrcreferral@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center at Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center, UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <email>CTRCReferral@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

